Protalix BioTherapeutics, Inc. (PLX) announced positive interim data from the first 14 patients that have completed, to date, the company's phase II clinical trial of OPRX-106 (oral anti-TNF) in patients with ulcerative colitis.
from RTT - Biotech http://ift.tt/2CGS7Zq
via IFTTT
No comments:
Post a Comment